dj: I sent in a check to Scottrade on Saturday. As soon as it clears I am actually going to buy more also. I just hope the share price stays under 80 cents. This will be my first purchase in years, and certainly my first above 50 cents a share. But we're finally moving forward with the cGMP facility, a point I had raised on this board over and over. I knew they could not compete for significant business without cGMP certification. And I still think that outside sales of synDNA will be our only significant revenue source for the next 5-7 years, unless a bigger player joins with us to produce a vaccine and gives us up-front money and milestone payments. So, while they might have long term in-house plans, the short term will be devoted to synDNA sales. Which is OK by me. Revenue is revenue. Profits are profits.
Market Data 
Markets 
AI
